MedPath

HAEMONETICS CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:0
Completed:10

Trial Phases

2 Phases

Phase 1:1
Not Applicable:2

Drug Approvals

17

FDA:17

Drug Approvals

CPDA-1 Blood Collection System

Approval Date
Jul 27, 2023
FDA

Leukotrap WB System

Approval Date
Jul 19, 2023
FDA

Leukotrap - AS-3

Approval Date
Jun 13, 2022
FDA

AS-3

Approval Date
Jun 13, 2022
FDA

Leukotrap - CP2D

Approval Date
Jun 13, 2022
FDA

Leukotrap WB System

Approval Date
Jan 26, 2022
FDA

Haemonetics Anticoagulant Sodium Citrate

Approval Date
Feb 2, 2021
FDA

Pall Sterile Cord Blood Collection Unit

Approval Date
Jun 3, 2020
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (66.7%)
Phase 1
1 (33.3%)

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

Completed
Conditions
Surgery
First Posted Date
2024-04-08
Last Posted Date
2024-04-08
Lead Sponsor
Haemonetics Corporation
Target Recruit Count
338
Registration Number
NCT06352125
Locations
🇺🇸

University of California - San Francisco, San Francisco, California, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

Ochsner Clinic, New Orleans, Louisiana, United States

and more 4 locations

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

Completed
Conditions
Healthy
First Posted Date
2024-02-15
Last Posted Date
2024-02-15
Lead Sponsor
Haemonetics Corporation
Target Recruit Count
181
Registration Number
NCT06261580
Locations
🇺🇸

Machaon Diagnostics, Oakland, California, United States

🇺🇸

Cardiovascular Research Institute - Loyola University Chicago Health Sciences, Maywood, Illinois, United States

🇺🇸

Louisiana Coagulation / Machaon Division, New Orleans, Louisiana, United States

IMPACT (Improving Plasma Collection) Clinical Trial

Not Applicable
Completed
Conditions
Apheresis Related Hypotension
First Posted Date
2020-03-25
Last Posted Date
2021-04-09
Lead Sponsor
Haemonetics Corporation
Target Recruit Count
3443
Registration Number
NCT04320823
Locations
🇺🇸

Octapharma Plasma, Spokane, Washington, United States

Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

Completed
Conditions
DOAC Eligible Subjects
First Posted Date
2016-06-14
Last Posted Date
2020-02-11
Lead Sponsor
Haemonetics Corporation
Target Recruit Count
385
Registration Number
NCT02798328
Locations
🇺🇸

Memorial Hospital South Bend, South Bend, Indiana, United States

🇺🇸

Essentia Institute of Rural Health, Duluth, Minnesota, United States

🇺🇸

Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States

and more 1 locations

Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

Not Applicable
Completed
Conditions
Transmission, Blood, Recipient/Donor
First Posted Date
2015-06-19
Last Posted Date
2022-04-29
Lead Sponsor
Haemonetics Corporation
Target Recruit Count
62
Registration Number
NCT02476851
Locations
🇺🇸

Haemonetics, Braintree, Massachusetts, United States

🇺🇸

Hoxworth Blood Center, Cincinnati, Ohio, United States

🇺🇸

American Red Cross Mid-Atlantic Region Blood Services, Norfolk, Virginia, United States

  • Prev
  • 1
  • 2
  • 3
  • Next

News

Vivasure Medical Secures CE Mark for First Fully Absorbable Large-Bore Vascular Closure System

Vivasure Medical has received European CE mark approval for PerQseal Elite, the first fully absorbable, sutureless closure system designed specifically for large-bore cardiovascular procedures.

© Copyright 2025. All Rights Reserved by MedPath